慢性淋巴细胞白血病的转移模式

The Cancer Journal Pub Date : 2019-11-01 DOI:10.1097/PPO.0000000000000417

N. Jain, S. O'brien

{"title":"慢性淋巴细胞白血病的转移模式","authors":"N. Jain, S. O'brien","doi":"10.1097/PPO.0000000000000417","DOIUrl":null,"url":null,"abstract":"Abstract Chemoimmunotherapy (CIT) was the standard treatment for patients with chronic lymphocytic leukemia for the last 2 decades. Recently, with the introduction of targeted therapies, the role of CIT has declined significantly. In the first-line setting, the role of CIT is limited to young fit patients with mutated immunoglobulin heavy chain variable region and without del(17p)/TP53 mutation. There is a limited role for CIT in relapsed chronic lymphocytic leukemia.","PeriodicalId":22430,"journal":{"name":"The Cancer Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"The Shifting Paradigm in Chronic Lymphocytic Leukemia\",\"authors\":\"N. Jain, S. O'brien\",\"doi\":\"10.1097/PPO.0000000000000417\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Chemoimmunotherapy (CIT) was the standard treatment for patients with chronic lymphocytic leukemia for the last 2 decades. Recently, with the introduction of targeted therapies, the role of CIT has declined significantly. In the first-line setting, the role of CIT is limited to young fit patients with mutated immunoglobulin heavy chain variable region and without del(17p)/TP53 mutation. There is a limited role for CIT in relapsed chronic lymphocytic leukemia.\",\"PeriodicalId\":22430,\"journal\":{\"name\":\"The Cancer Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Cancer Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/PPO.0000000000000417\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Cancer Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/PPO.0000000000000417","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 6

摘要

化学免疫疗法(CIT)是近20年来慢性淋巴细胞白血病患者的标准治疗方法。近年来，随着靶向治疗的引入，CIT的作用明显下降。在一线环境中，CIT的作用仅限于免疫球蛋白重链可变区突变且没有del(17p)/TP53突变的年轻健康患者。CIT在复发性慢性淋巴细胞白血病中的作用有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The Shifting Paradigm in Chronic Lymphocytic Leukemia

Abstract Chemoimmunotherapy (CIT) was the standard treatment for patients with chronic lymphocytic leukemia for the last 2 decades. Recently, with the introduction of targeted therapies, the role of CIT has declined significantly. In the first-line setting, the role of CIT is limited to young fit patients with mutated immunoglobulin heavy chain variable region and without del(17p)/TP53 mutation. There is a limited role for CIT in relapsed chronic lymphocytic leukemia.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Cancer Journal

自引率

0.00%

发文量

期刊最新文献

Effective Image Communication of Hormone Replacement Therapy Risks and Benefits Update on Pregnancy Following Breast Cancer Diagnosis and Treatment Concerns About Compounded Bioidentical Menopausal Hormone Therapy Menopausal Hormone Therapy and Breast Cancer Menopause Hormone Therapy in the Management of Postmenopausal Osteoporosis